NSE:NATCOPHARM 1 December 2025 - 8 December 2025

Natco Pharma shares fell nearly 3% to around ₹908 on 8 December 2025, despite the company completing a major acquisition in South Africa. The stock remains about 40% below its 52-week high, with year-to-date losses near 33%. Q2 FY26 revenue stood at ₹1,363 crore, almost unchanged from last year. Investors are weighing the drop in Revlimid earnings, higher R&D costs, and the ₹2,000-crore Adcock Ingram deal.

Natco Pharma shares traded at ₹933–₹936 on 2 December, up 3–3.5% but still down 34% over the past year. Q2 FY26 profit after tax reached ₹517.9 crore on revenue of ₹1,463 crore, with an EBITDA margin near 46%. Management warned the Revlimid windfall is fading, signaling lower profitability ahead. Trading volumes remain high as the stock rebounds from earlier losses.